Novavax and the European Commission have finalised an advance purchase agreement for up to 200 million doses of Covid-19 vaccines.
The initial transaction will involve 100 million doses of the new NVX-CoV2373 vaccine, but there will be the option for an additional 100 million doses through 2023.
This is a recombinant nanoparticle protein-based Covid-19 vaccine. The biotechnology company is currently working to complete its rolling submission for this type of vaccine to the European Medicines Agency in the third quarter of 2021, with delivery of initial doses expected to begin following approval.
President and CEO of Novavax Stanley C. Erck said: "We thank the European Commission for their partnership in this important step to expand vaccine